Clinical Trial: Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial
Brief Summary: To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.
Detailed Summary:
Sponsor: Sanofi
Current Primary Outcome:
- Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy) [ Time Frame: From the beginning to the end of the study ]
- Development of proteinuria [ Time Frame: From the beginning to the end of the study ]
- 20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation [ Time Frame: From the beginning to the end of the study ]
- body weight, blood pressure, pulse [ Time Frame: From the beginning to the end of the study ]
- Adverse effects of treatment [ Time Frame: From the beginning to the end of the study ]
Original Primary Outcome:
- Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy)
- Development of proteinuria
- 20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Sanofi
Dates:
Date Received: February 20, 2007
Date Started: July 2004
Date Completion:
Last Updated: November 17, 2010
Last Verified: November 2010
